Johnson & Johnson boosted its full-year outlook as it posted better-than-expected profit and sales in the second quarter. Bank of America's profit increase in the second quarter of 2025, which the ...

The company will also add a warning label to its drug Elevidys after the deaths of two teenage patients this year.

Following the death of two teenage patients with Duchenne muscular dystrophy following Elevidys treatment, Sarepta ...

Stocks rebounded on Wednesday after President Donald Trump denied reports that he was close to ousting Powell as chairman of ...

Shares of struggling drug developer Sarepta Therapeutics skyrocketed nearly 40% in extended trading Wednesday after the ...

The gene-therapy company is restructuring, laying off 36% of its workforce and making changes to its executive team.

Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover ...

The drastic cost-cutting move followa the deaths of two teenagers that forced the company to restrict usage of its gene ...

This is a developing story and will be updated as more information becomes available. | Sarepta Therapeutics has laid off 500 staffers, or 36% of its workforce, as part of a strategic restructuring ...

This summary highlights significant events in the health sector, including Johnson & Johnson's profit boost from Darzalex, safety concerns for GSK's cancer drug, refugee malnutrition in Gaza, KKR's ...

Sarepta Therapeutics (NASDAQ:SRPT) surges 40% post-market after strategic restructuring, workforce cuts, pipeline focus, and ...

Sarepta Therapeutics said on Wednesday it would lay off 36% of its workforce, or about 500 employees, after two recent deaths of patients who had received its gene therapy, Elevidys. Shares of the ...